Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents.

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-11-22 DOI:10.1080/14737167.2024.2410257
Raphael Wittenberg, Jacqueline Damant, Amritpal Rehill, Martin Knapp, Tobi Adeyemi, Ian Matthews
{"title":"Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents.","authors":"Raphael Wittenberg, Jacqueline Damant, Amritpal Rehill, Martin Knapp, Tobi Adeyemi, Ian Matthews","doi":"10.1080/14737167.2024.2410257","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While medical costs of chickenpox have been researched, little is known about indirect costs. Understanding total costs is important for decisions about vaccination. This study estimated the value of lost productivity of adults missing work to care for children with chickenpox.</p><p><strong>Research design and methods: </strong>It comprised an international literature review, an online survey of 1,526 parents of children aged 1-11 years, and computation of indirect costs of chickenpox in the UK. The survey covered chickenpox episodes amongst respondents' children, time children took off school/nursery, and work absenteeism by parents/caregivers caring for them.</p><p><strong>Results: </strong>Respondents reported on 2,283 children, of whom 52% (1185/2283) experienced chickenpox. Almost half (591/1185) missed days of school/nursery, averaging 5.6 days missed. In 260 cases of 542 adults providing data with such a child, an adult missed work to care for the child. The daily value of this lost productivity was £170. There were approximately 200,000 GP consultations for chickenpox and 625,000 births annually, suggesting the annual chickenpox incidence lies between these figures. The estimated annual UK productivity loss due to chickenpox is £20-£70 million ($25-$90 million).</p><p><strong>Conclusions: </strong>Annual value of lost productivity due to chickenpox is in range £20 to £70 million.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"197-203"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2410257","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: While medical costs of chickenpox have been researched, little is known about indirect costs. Understanding total costs is important for decisions about vaccination. This study estimated the value of lost productivity of adults missing work to care for children with chickenpox.

Research design and methods: It comprised an international literature review, an online survey of 1,526 parents of children aged 1-11 years, and computation of indirect costs of chickenpox in the UK. The survey covered chickenpox episodes amongst respondents' children, time children took off school/nursery, and work absenteeism by parents/caregivers caring for them.

Results: Respondents reported on 2,283 children, of whom 52% (1185/2283) experienced chickenpox. Almost half (591/1185) missed days of school/nursery, averaging 5.6 days missed. In 260 cases of 542 adults providing data with such a child, an adult missed work to care for the child. The daily value of this lost productivity was £170. There were approximately 200,000 GP consultations for chickenpox and 625,000 births annually, suggesting the annual chickenpox incidence lies between these figures. The estimated annual UK productivity loss due to chickenpox is £20-£70 million ($25-$90 million).

Conclusions: Annual value of lost productivity due to chickenpox is in range £20 to £70 million.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
英国儿童水痘造成的生产力损失估计值:一项对家长的调查。
背景:虽然对水痘的医疗成本进行了研究,但对间接成本却知之甚少。了解总成本对疫苗接种决策非常重要。本研究估算了成年人因照顾水痘患儿而缺勤所损失的生产力价值:研究包括国际文献综述、对 1,526 名 1-11 岁儿童的家长进行的在线调查以及英国水痘间接成本的计算。调查内容包括受访者子女的水痘发病情况、子女的休学/入托时间以及照顾子女的父母/护理人员的缺勤情况:受访者报告了 2283 名儿童的情况,其中 52%(1185/2283)的儿童出过水痘。近一半的儿童(591/1185)缺课,平均缺课天数为 5.6 天。在提供数据的 542 位成年人中,有 260 位成年人因照顾孩子而缺勤。这种生产力损失的日价值为 170 英镑。每年大约有 20 万名全科医生会诊水痘,62.5 万名新生儿出生,这表明水痘的年发病率介于这两个数字之间。据估计,英国每年因水痘造成的生产力损失为 2,000 万至 7,000 万英镑(2,500 万至 9,000 万美元):结论:水痘造成的年生产力损失价值在 2,000 万英镑至 7,000 万英镑之间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Pharmacoeconomics & Outcomes Research
Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
CiteScore
4.00
自引率
4.30%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024. Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities. Cost comparison of F(ab')2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis. Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1